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Abstract
Infection with SARs-COV-2 displays increasing fatality with age and underlying co-morbidity, in particular, with
markers of the metabolic syndrome and diabetes, which seems to be associated with a “cytokine storm” and an
altered immune response. This suggests that a key contributory factor could be immunosenescence that is both
age-related and lifestyle-induced. As the immune system itself is heavily reliant on mitochondrial function, then
maintaining a healthy mitochondrial system may play a key role in resisting the virus, both directly, and indirectly
by ensuring a good vaccine response. Furthermore, as viruses in general, and quite possibly this new virus, have
also evolved to modulate immunometabolism and thus mitochondrial function to ensure their replication, this
could further stress cellular bioenergetics. Unlike most sedentary modern humans, one of the natural hosts for the
virus, the bat, has to “exercise” regularly to find food, which continually provides a powerful adaptive stimulus to
maintain functional muscle and mitochondria. In effect the bat is exposed to regular hormetic stimuli, which could
provide clues on how to resist this virus. In this paper we review the data that might support the idea that
mitochondrial health, induced by a healthy lifestyle, could be a key factor in resisting the virus, and for those
people who are perhaps not in optimal health, treatments that could support mitochondrial function might be
pivotal to their long-term recovery.
Introduction
The risk of severe morbidity associated with infection by
SARS-CoV-2 rises with age and underlying co-
morbidities, which indicate that up to 1.7 billion people,
or 22% of the global population, could be at severe risk;
the increased risk seems to be largely associated with an
imbalanced and/or an excessive inflammatory response
[1]. One suggestion is that the severity could be related
to a failure of inflammation resolution, leading to pul-
monary hyper-inflammation and “cytokine storms” [2].
With increasing age there is often an exaggerated innate
immune response to respiratory infections [3] and rising
inflammatory tone [4, 5]. Overall, it seems that suscepti-
bility to the virus is related to an age-related loss of
adaptive immunity combined with an increased innate im-
mune response [6]. This “inflammaging” seems to be asso-
ciated with T-cell immunosenescence and thymic atrophy;
critically, exercise seems to be protective [7]. The protect-
ive effect of exercise is informative, as the pathological
severity of SARS-CoV-2 infection seems to be associated
with many obesity-related co-morbidities, such as diabetes
[8–10], in contrast, physical fitness is emerging as a pre-
ventative strategy against the virus [11].
This suggests that as well as age, lifestyle could be im-
portant in determining susceptibility to the virus. We
have suggested that a modern sedentary lifestyle has
effectively removed exogenous hormetic stimuli, such as
physical activity, which is leading to an accelerated age-
ing phenotype [12]. In short, a modern lifestyle could be
accelerating the process of “inflammaging”: obesity is as-
sociated with a pro-inflammatory state, increased inflam-
matory macrophages and altered T-cell homeostasis
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[13]. In contrast, exercise is largely anti-inflammatory,
which is thought to explain its many benefits [14, 15]. A
key player in this adaptation is the mitochondrion, as
mitochondrial stress enhances mitochondrial function
not only in muscle, but in multiple other organs with
myokines playing a key role [16, 17]. For example irisin,
which protects mitochondria, can protect against ischae-
mia/reperfusion (IR) injury in the lung [18]. Irisin has
also been found to favourably alter genes in adipocytes
that are affected by the SARS-CoV-2 [19] and to modu-
late macrophage reactive oxygen species (ROS), display-
ing anti-oxidant and anti-inflammatory properties [20].
Critically, exercise can enhance mitochondrial function
and capacity in peripheral blood mononuclear cells
(PBMCs) [21].
As mitochondria are pivotal in the immune response
and many viruses in turn modulate mitochondria [22,
23], it is possible that altered mitochondrial function
may explain at least some of the variance in responses to
SARS-CoV-2. As most cells in the body contain mito-
chondria, including immune cells, this would be
expected and is now embraced by the concept of
“immunometabolism”. This is perhaps most clearly seen
in the clinical phenotype of subjects with inherited mito-
chondrial defects who often display immunodeficiency
and a much higher rate of infections – highlighting the
reliance of the immune system on mitochondria [24,
25]. Although this is relevant to resistance to the virus, it
is also perhaps relevant to the efficacy of vaccines;
Thacker and colleagues, using gene expression assays of
PBMCs, have shown that there is an age-related decrease
in response to influenza vaccines, which appears to be
linked to decreased mitochondrial function [26]. In
short, compromised mitochondrial function, either due
to genetic factors, extreme age, or lifestyle, could have a
bearing on both resistance to the virus and the ability to
mount an effective response to a vaccine.
It therefore seems that maintaining “mitochondrial
health” is vital, which probably correlates with an effective
mitochondrial reserve induced by factors like physical ac-
tivity, such that when the system is “stressed” (e.g., by a
virus), it can cope. Although the virus may only infect cer-
tain cells, the immune response is global and dependent
on mitochondrial function in multiple tissues and organs.
What is clear is that severity is associated with the hyper-
inflammation syndrome and involves dysregulation of
many different cell types [27]. This is to be expected, as
throughout evolution, viruses have evolved to manipulate
the immune system to hide from it, and can invoke im-
munosuppression, which in itself can become patho-
logical, for instance, by modulating T-cells [28, 29].
It now seems that the spike protein of SARS-CoV-2
can bind to T-cell receptors (TCRs), acting as a super-
antigen and causing excessive activation of the adaptive
immune system – potentially resulting in the hyperin-
flammatory syndrome [30]. This is perhaps relevant as
persistent antigenic stimulation can lead to T-cell ex-
haustion, which is associated with decreased oxidative
phosphorylation and loss of mitochondrial function des-
pite enhanced glycolysis – but can be reversed using
anti-oxidants [31]. Data is now showing that COVID-19
patients do have populations of T-cells displaying mito-
chondrial dysfunction, as well as altered mitochondrial
markers in monocytes – hinting that immune-metabolic
phenotyping could be used to understand disease patho-
genesis and possible treatments; this could include tar-
geting mitochondria [32]. In short, the immune system
itself could well be a target for this virus. Apart from the
virus targeting the TCR as a super antigen, there is
evidence that other than it binding to the angiotensin
converting enzyme (ACE) as its main receptor, it may
also bind receptors on immune cells, such as CD147 and
CD26 [33], or neuropilin-1 (Nrp-1) [34, 35].
We have structured this paper to first review the now
established data on general mitochondrial function and
health in relation to “inflammaging”, followed by the evi-
dence suggesting that the SARS-CoV-2 virus itself ma-
nipulates mitochondrial function and what we might
learn from bats – which are thought to be its natural
host. From this we propose that a poor lifestyle acceler-
ates “inflammaging” which is associated with mitochon-
drial ill-health, and in some populations this predisposes
them to a worse outcome. In the second part of the
paper we discuss the implication of this idea in relation
to current and suggested drug-based treatments and vac-
cine efficacy, the “long-COVID” syndrome, as well as
how environmental factors may make some people more
vulnerable. Understanding these concepts may help in-
form clinical strategy.
Mitochondrial function in inflammaging and
immunosenescence
Circulating extracellular vesicles (EVs) derived from im-
mune cells seem to have emerged as a means of studying
immunosenescence. In particular, they show an age-
related decline in mitochondrial function – which could
be related to dysfunctional mitophagy [36]. In fact, mice
engineered to have dysfunctional T- cell mitochondria
display accelerated senescence and “inflammaging”,
highlighting the point that T-cells can determine organ-
ismal fitness and lifespan [37]. This does support data
indicating the importance of a healthy T-cell response in
defending against the virus [38, 39].
The underlying aetiology for “inflammaging” has long
thought to be associated with mitochondrial dysfunction
as suggested by Nick Lane in 2003 in his “double agent”
theory [5], and is now receiving renewed interest, for in-
stance, in how decreasing mitochondrial function can
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reduce T-cell function and enhance immune senescence,
as mitochondria are pivotal in metabolic reprogramming
towards the Warburg effect [40]. Indeed, as mitochon-
drial dysfunction can lead to “inflammaging”, the ob-
served increase in older people of mitokines could be an
attempt by the system to restore homeostasis as many
are anti-inflammatory. Unfortunately, for many, this re-
sponse doesn’t fully compensate [41]. This is why
“exogenous” factors, such as physical activity or calorie
restriction seem to be required to optimise function;
these were normal factors during evolution, but are not
in our modern sedentary and obesogenic environment.
One aspect of ageing is a failure to remove damaged
components, for instance, dysfunctional mitochondria
via mitophagy, which could lead to immune dysfunction
[42]. It has been suggested that imbalances in mitochon-
drial mass could be responsible for ageing-related T-cell
subset dysfunction [43], which would suggest a failure of
mitophagy. Indeed, activation of mitophagy/autophagy is
thought to be a pivotal mechanism in slowing ageing
and inhibiting inflammation during calorie restriction
(CR) [44]: CR/intermittent fasting has been suggested as
a defence against the SARS-CoV-2 as it is anti-
inflammatory [45]. In contrast, a modern sedentary life-
style is also contributing to “inflammaging”, which acts
as a common mechanism linking sarcopenia, obesity,
cardiomyopathy and dysbiosis, with over-activation of
nod-like receptor pyrin family domain containing 3
(NLRP3) inflammasomes and mitochondrial dysfunction
playing key roles [46]. Overall, this all seems to support
a close link between immunosenescence, inflammaging
and failing mitochondrial function.
Does SARS-CoV-2 modulate mitochondrial
function, either indirectly or directly, and if so, in
what cells?
The above suggests that there is a close link between
mitochondrial dysfunction and immunosenesence, which
could lead to an increased chance of an imbalanced im-
mune response to SARS-CoV-2. This could take the
form of both an inability to clear it, but also an exagger-
ated pro-inflammatory response and a “cytokine storm”.
However there could also be another factor, and that is
that the virus is modulating mitochondrial function to
help it replicate.
One clue to this possibility is that many viruses do ap-
pear to manipulate bioenergetics towards aerobic
glycolysis (the “Warburg effect”); this is a highly energy-
dependent process to help generate substrates to build
new virus particles [47]. Aerobic glycolysis does require
healthy mitochondria, and is a normal process in mul-
tiple cell types, including immune cells [48]. Perhaps
tellingly, data suggest that successful clonal expansion of
vaccine-elicited T-cells is heavily depending on
mitochondrial function [49]. What this suggests is that
any cell forced to produce new viruses, if its mitochon-
dria are not functioning optimally, could rapidly become
energy deficient and be more likely to die, and depend-
ing on its type and location, could either enhance in-
flammation and/or compromise the immune response.
What are the SARS-CoV-2 receptors and where are they
found?
The direct impact of the virus will depend on which cells
it infects. To date, most evidence points towards ACE2
being the primary receptor for this virus. Early data sug-
gested ACE2 is predominantly expressed in pulmonary
alveolar type 2 progenitor (AT2) and respiratory epithe-
lial cells, but is also expressed in myocardial, illium and
oesophagus, as well as some kidney cells – with little ex-
pression in immune cells [50]. Elevated ACE2 expression
has also been found in the olfactory neuroepithelium,
potentially explaining the anosmia that some patients
have suffered [51]. More recent data has suggested that
ACE2 may be primarily expressed in bronchial transient
secretory cells [52].
Perhaps of relevance to the increased risk associated
with obesity is that high ACE2 expression has been
found in both visceral and subcutaneous adipose tissue;
this is important as adipose tissue in obesity is well
known to secrete higher levels of angiotensin 2, an in-
flammatory component of the renin-angiotensin aldos-
terone system (RAAS), which is key in driving many of
the pathological complications associated with this con-
dition [53]. Critically, obesity also seems to be associated
with increased expression of ACE2 in the lung, and en-
hanced inflammatory markers and dysregulated lipogen-
esis; viruses are well known to hijack lipid metabolism as
part of their life cycle [54].
Although ACE2 is not highly expressed in immune
cells, it is possible that other proteins expressed on im-
mune cells could be acting as SARS-CoV-2 receptors,
such as CD26 (also known as dipeptidyl peptidase 4,
DPP4) or CD147 (also called basigin). CD147 can be
activated by cyclophilins, which are inhibited by cyclo-
sporine A. Critically, the expression of these potential
receptors changes with age, as well as with co-morbid
conditions, such as obesity and hypertension [33]. Thus
both CD147 and cyclophilin A have been suggested as
potential targets for treating the virus. For example,
cyclosporine is very effective against corona viruses;
however, its immunosuppressive actions would limit its
usefulness [55].
CD147 and ACE2 expression is often increased in lung
disease, resulting in excessive activation of the RAAS
and enhancing damage, which could, in part, explain the
origins of the cytokine storm. It has been suggested that
melatonin, a potent natural anti-oxidant, could suppress
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the CD147 inflammatory pathway and help in treating
COVID-19 patients [56]. In silico binding studies do
seem to support the possibility that the virus does in-
deed use CD147 as a receptor, and could, potentially, ex-
plain why lymphopenia is associated with severity of
COVID-19 and a loss of T-cell subsets [57].
Data is indicating that this virus may also bind to
neuropilin-1 (Nrp-1); this protein is expressed on many
cells, including those in the central nervous and immune
systems, and is also a receptor for vascular endothelial
growth factor A (VEGF-A) [34, 35, 58]. Apart from sug-
gesting it can thus potentially infect the central nervous
system (CNS), it also appears that SARS-CoV-2 can in-
duce analgesia – which could aid in increased disease
transmission in asymptomatic individuals [59]. Nrp-1 is
also a focus for immunotherapy treatments in oncology,
as it is expressed on subsets of regulatory T-cells [60].
There is also data indicating it is expressed in the
cardiovascular system; if its expression is reduced, it re-
sults in cardiac mitochondrial dysfunction as it controls
the master mitochondrial regulator, peroxisomal
proliferator-activated receptor γ coactivator 1α (PGC1α),
as well as peroxisomal proliferating activating receptor γ
(PPARγ) [61].
This data does suggest that the virus not only modu-
lates essential components of the RAAS affecting inflam-
matory balance via ACE2, but if it is also modulating the
T-cell response directly, for instance, via CD147, or the
TCR, or even, Nrp-1.
Do SARS viruses code for proteins that target
mitochondria?
In SARS-CoV-1 the open reading frame-9b (ORF-9b)
encodes for a protein that locates to the mitochondrion.
Here it induces fusion by triggering degradation of
dynamin-like protein 1 (DRP-1), while inhibiting mito-
chondrial anti-viral signalling proteins (MAVS). This is
thought to underlie its ability to suppress the anti-viral
interferon response. It can also induce autophagy and
activate NF-κB [62]. MAVS are small proteins that on
detection of double stranded RNA (dsRNA) oligomerise
on mitochondria to form a signalling platform and initi-
ate interferon signalling, as well as cell death [63, 64]. It
also seems that MAVS can act as adaptor proteins for
NLRP3, forming a complex with mitochondria, although
the inflammasome can also be activated in a way that
doesn’t induce an interferon response, but can induce
the interleukin beta (IL-β) response [65].
With regards SARS-CoV-2, protein interaction map-
ping shows that it shares a great deal of homology with
SARS-CoV-1, but significantly, several of its proteins are
also predicted to directly interact with mitochondria,
such as non-structural proteins (NSPs) 4 and 8, and
ORF9c, as well as components of the interferon and NF-
κB pathways [66]. This, because of the well described
role of viruses in manipulating mitochondrial function,
has led to other groups suggesting that indeed, mito-
chondrial “hijacking” by SARS-CoV-2 could be a key
factor in the pathogenesis of this virus [67].
Many viruses also use viroporin proteins that can
oligomerise to help viral entry and release, as well as
control intracellular signalling ions, such as calcium or
potassium. They can also, via direct protein interaction,
manipulate signalling pathways. The host cell detects
these as changes in ions levels and ROS, and via, for
instance, the NLRP3 inflammasome, activates cellular
defence [68]. SARS-CoV-1 has at least three viroporins,
two of which are essential for replication and virulence
[69]; the E protein, in particular, not only seems to trig-
ger P38 MAPK activity, but also seems to modulate
calcium flux by acting as a permeable ion channel in
endoplasmic reticulum-Golgi intermediate compartment
(ERGIC)/Golgi membranes, activating the inflamma-
some [70]. SARS-CoV-2 seems to have a similar E
viroporin that induces ionic imbalance [71]. From the
calcium and ROS signalling perspective this is particu-
larly important, as mitochondria are not only pivotal in
calcium buffering and signalling, but are also controlled
by calcium [72]. Data suggest that many viruses form
viral “factories”, which are constructed from host cell
membranes, and are often tightly coupled to mitochon-
dria to provide precursors and energy – this includes the
Coranoviridae [73, 74].
SARS-Cov-2 may enhance aerobic glycolysis to favour
replication
Emerging data is now suggesting that T-cell mediated
immunity may be playing a powerful role in protecting
against the virus, as many asymptomatic people, or those
who have only had mild symptoms, show low levels of
anti-SARS-CoV-2 antibodies but a strong T-cell medi-
ated response against the virus. In contrast, more severe
disease is associated with more rapid seroconversion and
the presence of inflammatory markers, such as C-
reactive peptide (CRP) [75, 76]. In fact, it now appears
that the severity of infection positively correlates with a
decreased type 1 interferon (IFN1) response, but an ex-
aggerated inflammatory response, characterised by high
levels of interleukin 6 (IL-6) and tumour necrosis factor
alpha (TNFα) – possibly related to excessive activity of
nuclear factor kappa B (NF-κB). This latter finding could
be related to an auto-inflammatory loop in the lungs
[77]. It does seem that in some people that the transcrip-
tional response to SARS-CoV-2 is imbalanced, with a
less than optimal interferon-I and -III response, but an
exaggerated chemokine one; this may represent an
evolved manipulation of the immune system by the virus
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that worsens the outcomes for older patients with co-
morbidities as they cannot clear the virus properly [78].
Data from autopsies of deceased COVID-19 patients
show that tissue inflammation and organ dysfunction do
not map to the cellular distribution of the virus, hinting
at tissue-specific tolerance. In fact, severe inflammatory
changes seem to be largely restricted to the lungs and
the reticulo-endothelial system. This suggested that
COVID-19 related deaths were due to immune-
mediated, rather than pathogen-mediated organ inflam-
mation and injury [79]. It may therefore be relevant that
IFN1 can also have some anti-inflammatory actions,
modulating for instance, NLRP1/3 inflammasomes and
inhibiting interleukin-1 (IL-1) production [80]. Type 1
interferons are key in modulating T-cell responses and
resistance to viruses [81, 82].
It had been suggested that as the virus uses ACE2 as a
receptor on the cell surface it could trigger activation of
the renin-angiotensin-aldosterone system (RAAS), which
in turn, leads to hyperactivation of the NLRP3 inflam-
masome and pyroptosis, a form of cell death that results
in inflammatory amplification [81]. Data does now seem
to support this and has been shown in various types of
human stem cells – which could potentially affect tissue
regeneration [83]. ACE2 cleaves angiotensin II to gener-
ate angiotensin (1–7), which is largely anti-inflammatory
and protective [84]. Critically, mitochondria have a func-
tional angiotensin system [85], and ACE2 seems to be
mitochondrially protective [86]. Potentially of interest
here is that a product of ACE2, angiotensin-(1–9), seems
to inhibit mitochondrial fission in the heart, enhancing
mitochondrial fusion and calcium buffering and protect-
ing against cardiac hypertrophy [87]. It is thus possible,
by binding to ACE2, the virus may suppress a counter-
balancing anti-inflammatory pathway that affects mito-
chondrial function.
So why would SARS-CoV-2 do this? One possible ex-
planation is that the virus affects the most prevalent im-
mune cells in the lungs, monocytes/macrophages,
inducing them to shift metabolically to aerobic glycoly-
sis, which favours viral growth. The infection, in the
presence of oxygen, seems to achieve this by triggering
mitochondrial reactive oxygen species (ROS) production,
stabilising the hypoxia-inducible factor-1α (HIF-1α),
which in monocytes, consequently inhibits T-cell re-
sponses and lung epithelial cell death. It seems that
high glucose levels induce viral replication [88].
Furthermore, the inflammasome can also modulate
glycolysis; in macrophages, this may be a key process
in metabolic reprogramming [89]. Critically, inflam-
masome activation can be inhibited by nuclear factor,
erythroid 2-like 2 (Nfe2l2/Nrf2), which is pivotal in
enhancing antioxidant defences and suppressing in-
flammation [90]; it therefore counterbalances NF-κB,
which is also redox activated, but central to the im-
mune response [91].
Another key factor is that the SARS-CoV-2 genome
encodes proteins that can target the NF-κB pathway
[66]. SARS-COV-2 therefore seems to induce a Warburg
shift (aerobic glycolysis), which is a tactic that many
other viruses, and cancer cells, use [47]. It is thus of rele-
vance that that the metabolic reprogramming induced
by SARS-CoV-2 can be suppressed by melatonin [92],
which is a powerful antioxidant that protects mitochon-
dria [93]. In fact SARS-CoV-2 also seems to induce
activation of pathways like p38 mitogen activated protein
kinase (MAPK), which results in cell cycle arrest, inhib-
ition of apoptosis, and results in a feed-forward inflam-
matory loop [94]; the systems it targets therefore do
seem have much in common with those that are altered
in cancer [95]. Critically, MAPKs also modulate mito-
chondrial function, for instance, interacting with the
voltage dependent anion channel 1 (VDAC1) [96]. This
seems to add up to the virus manipulating several path-
ways to invoke aerobic glycolysis, which must involve
mitochondrial function.
Diabetes is also associated with activation of p38
MAPK via ROS generated by glucose induced mitochon-
drial dysfunction that can be offset by targeted mito-
chondrial antioxidants [97, 98]. Not only is diabetes a
risk factor for a worse outcome when infected with
SARS-CoV-2, but the virus itself may induce a worsen-
ing of the condition [99–101]. Indeed, it now seems that
fasting blood glucose is a predictor of mortality for
COVID-19 patients [102]. Overall, prediabetes and/or
type 2 diabetes (T2D) itself is embraced by the concept
of the metabolic syndrome in which insulin resistance,
mitochondrial dysfunction and inflammation are all
components [12]. Metformin, which modulates
mitochondrial function, is a key treatment for T2D [103]
– and has shown some benefit in COVID-19 patients
[104, 105]. In contrast, evidence indicates that the in-
flammatory effect of the Western diet may induce acti-
vation of the NLRP3 inflammasome [106]. In light of the
emerging data, this could only worsen the potential for
an exaggerated inflammatory response.
SARS-CoV-2 could lead to mitochondrial stress
It is therefore likely that SARS-CoV-2 does modulate
mitochondrial function. So it could be surmised, for in-
stance, that this virus could ensure close tethering of
mitochondria, and via calcium flux, stimulate their func-
tion. Clearly, if this process was too overwhelming, or
the mitochondria were already functionally compro-
mised, this would rapidly lead to mitochondrial stress.
With regards this, Singh and colleagues have highlighted
an interesting link with viruses and the production of
mitochondrially-derived vesicles (MDVs), which are
Nunn et al. Immunity & Ageing           (2020) 17:33 Page 5 of 21
normally part of a system to remove damaged compo-
nents from the mitochondrion [67]. If, like SARS-CoV-1,
this new virus also does this, and also induces mitochon-
drial fusion, it hints at an interesting ability to prevent
apoptosis, as well as mitophagy, but stimulate a mechan-
ism to move virus particles around. If it is also inhibiting
MAV activity, then the mitochondrion might not initiate
interferon signalling, but might still continue, potentially
by producing higher than normal levels of ROS, to
stimulate inflammasome activity and metabolic repro-
gramming towards glycolysis. In effect, the virus
repurposes the normal inflammatory metabolic
reprogramming towards aerobic glycolysis, which in-
volves modulation of mitochondrial function, but man-
ages to suppress the normal anti-viral interferon
response. In many tissues, the system may manage to stay
in balance and not cause an overt over activation of the
immune system, but in the lungs, it seems that in some
people, this balance is lost. Figure 1 summarises this.
The immune system, hormesis and mitochondria
As indicated, if the virus is modulating mitochondrial
function in a variety of cell types, either directly, or in-
directly, then the more robust the mitochondrial system,
Fig. 1 Viruses like SAR-CoV-2 manipulate cellular metabolism leading to the potential for a feed-forward inflammatory loop.
Viruses have evolved to usurp their host’s cellular machinery to make more viruses. One common mechanism is to suppress apoptosis and
manipulate the immune system to inhibit specific anti-viral programmes, which usually means interferons, while stimulating a shift towards aer-
obic glycolysis to provide precursors to build new viruses. However, this latter ability repurposes pathways that are often involved in generalised
immunity that both increase the production of pro-inflammatory mediators, while metabolically reprogramming immune cells. In the case of
SARS-CoV-2 this may well result in a feed-forward pro-inflammatory loop in the lungs, which seems to be driven by monocytes/macrophages
switching to aerobic glycolysis and is driven my mitochondrial ROS and stabilisation of HIF-1α; in turn, this metabolic shift suppresses T-cells and
the interferon response [88]. This process is accentuated as the virus may well stimulate inflammasome activation [81], while if it is similar SARS-
CoV-1, it could also suppress MAVS formation and activate NF-kB [62]; protein interaction mapping does suggest this is the case [66]. As it is likely
that inflammasome activation can also invoke glycolysis [89], then the evolutionary rationale seems sound. Of particular importance here is also
the balance between NF-kB and Nrf2, which more or less seem to counter-balance each other, as Nrf2 is pivotal in suppressing excessive oxi-
dative stress [91]. For more detailed reviews of the role of mitochondria in the immune response see [22, 107]
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the greater the chance of the system being able to resist
the virus. In general, hormetic factors, such as exercise,
seem to be necessary to maintain mitochondrial health
throughout the body; this phenotype is associated with a
more balanced immune response and minimisation of
“inflammaging”. In this section we review why this is,
and look at why one of the natural hosts of the virus, the
bat, may be able to resist.
A robust mitochondrial system and effective immune
system may rely on hormesis
A key component of effective immunity is now thought
to be a healthy mitochondrial system [107], while an
underlying unifying element to both the ageing process
and conditions associated with a poor lifestyle is a deg-
radation in overall mitochondrial function/reserve and a
rise in oxidative stress and inflammation [4, 5]. An im-
portant factor in the maintenance of mitochondrial
function is hormesis where low levels of stress induce an
over-compensatory response that induces positive adap-
tations, enabling an organism to better tolerate the stres-
sor next time they encounter it. For example, an
effective hormetic response can be induced by sub-lethal
doses of physical activity, calorie restriction and many
plant polyphenols [12], with mitochondrial stress being a
key trigger [108]. This results in an enhanced respiratory
reserve and anti-oxidant capacity, and a greater ability to
manage the ATP/ROS ratio when placed under stress
[109]. Certainly, small, long-lived species like bats and
sparrows, when compared to comparatively much
shorter lived species like mice, do demonstrate lower
levels of mitochondrial hydrogen peroxide release [110].
Given that mitochondrial dysfunction is strongly corre-
lated to immune dysfunction and chronic inflammation
[111], then inflammation resolution is probably going to
be best achieved by ensuring healthy mitochondrial
function as it ensures that ROS release does not get out
of control.
What can bats tell us?
The concept of hormesis suggests that it is important to
constantly stimulate the renewal and maintenance of a
large population of healthy mitochondria. It may there-
fore be possible to learn something from one of the nat-
ural hosts of SARS-CoV-2, bats [112]. Bats are the only
true flying mammal and are exceptionally long-lived for
their size. This could be because the evolution of flight
has required a whole host of adaptations, including
maintaining a large pool of mitochondria that produce
very little ROS while maintaining a high ATP output.
This appears to have gone hand-in-hand with changes in
the immune system to prevent excessive inflammatory
activation by stressed mitochondria, for instance, by
dampening NLRP3 Inflammasome activity. The net
result is that many bats can tolerate high levels of vi-
ruses, like the Coronaviridae family [113–116] and do
show a reduced antibody and inflammatory response,
hinting they are using another part of their immune sys-
tem to control the virus [117].
The inflammasome may thus be important, as its acti-
vation can lead to pyroptosis, an inflammatory form of
apoptosis, and can be triggered by excessive mitochon-
drial stress [118]. It may well be an essential component
in “inflammaging” [42]. There is some evidence that at
least in some species of bat, mitochondrial health, des-
pite bursts of oxidative stress, is maintained by stringent
mitochondrial quality control mechanisms, like mito-
phagy [119]. Mitophagy is in fact a negative regulator of
NLRP3 inflammasome activity, so although mitochon-
drial damage can activate the inflammasome, it can also
activate counter-balancing mitophagy to prevent exces-
sive inflammation [120]. In short, it seems that powered
flight has required the co-evolution of both mitochon-
dria that tightly control ROS, and a co-adapted immune
system.
Critically, there is evidence that SARS-CoV-2 inhibits
autophagy [121], suggesting it might also inhibit mito-
phagy. If this virus does indeed induce mitochondrial fu-
sion, as SARS-CoV-1 may do [62], then this would fit, as
mitochondrial fusion can inhibit mitophagy, and can in-
hibit cell death and ensure energy production, although
prolonged fusion can also initiate cell death in some
circumstances [122]. This latter point suggests another
innate anti-viral mechanism. Overall, modulation of the
inflammasome could be one element in how the virus
could result in an “inflammaging” phenotype.
Humans, hormesis, exercise and the immune system
The effects of hormesis, certainly for humans, are per-
haps most clearly seen in response to exercise training,
in particular, aerobic training, where both mitochondrial
capacity and function is increased in young and old
[123, 124]. This is matched by increased survival and
healthier ageing in cohorts who undertake plenty of
physical activity [125]. Active muscle is generally inflam-
matory, but commensurately induces counterbalancing
powerful anti-inflammatory and anti-oxidant mecha-
nisms throughout the body. Exercise thus appears to
show a biphasic dose response and the evidence is build-
ing that as long as it is not done excessively, in particu-
lar, allowing time for recovery, it is highly beneficial:
over time the adaptive over-compensation includes an
improved anti-inflammatory and anti-oxidant feedback
(25-28) [126].
Muscle has now been shown to have other functions,
like harbouring and supplying anti-viral stem T-cells,
hence, antagonising T-cell exhaustion and protecting
proliferative potential during inflammation [127]. In
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contrast white adipose tissue plays a key role in adaptive
immunity, and in excess, contributes to the altered im-
mune function and chronic inflammation often associ-
ated with obesity [128]. In particular, excessive visceral
adipose tissue (VAT), seems to play a pivotal role in
obesity-related pathogenesis; critically, its volume is de-
creased by exercise [129]. Furthermore, not only does
type 1 interferon unlock dormant adipocyte inflamma-
tory potential [130], but exercise reduces adipose expres-
sion of NLRP3 [131]. It therefore seems that adipose
tissue and muscle play a yin-yang role in the immune re-
sponse, whose set point will thus be determined by an
individual’s fitness and calorie balance, and overall mito-
chondrial capacity and health, and thus, reserve. In
short, mitochondrial reserve, and thus spare respiratory
capacity, is pivotal in enhancing the “healthspan”, and is
greatly improved by exercise [109]. The key here is that
stress can be signalled from mitochondria in any tissue
to the rest of the body by way of “mitokines”; muscle ac-
tivity is a prime inducer of mitochondrial stress [132].
Mitochondrial reserve and redox
It therefore seems that control of inflammation is associ-
ated with tight control of mitochondrial ROS, which is
itself dependent on “mitohormesis” by factors such as
exercise, plant compounds in the diet, and calorie re-
striction [108, 133]. The basis for this is that life is based
on redox and compartmentalised production of ROS as
part of a signalling system [134, 135]. This has led to
redox theories of disease and ageing, focussing on the
mitochondrion [136] and their role in generating an age-
related rise in inflammatory tone [5], which supports the
pivotal role of mitochondria in the immune system [137]
and in resistance to infections including viruses [138]. In
support of this, there is increasing evidence that mito-
chondria can also act as net sinks of ROS and this is
linked to lifespan. For instance mitochondria from the
long lived naked mole rat (NMR) produce less ROS than
comparable shorter lived animals [139, 140]. Further-
more the mitochondria in NMR, and bats, also appear to
be able to maintain a depolarisation of the inner mem-
brane for much longer during their life cycle, which is a
key mechanism to reduce ROS production during ageing
[141]. A key idea that relates to this is the Redox-
Optimised ROS Balance (R-ORB) hypothesis, which stip-
ulates that mitochondrial emission of ROS will reach a
nadir when respiratory rate reaches a maximum – in ef-
fect, mitochondria will maximise ATP production and
minimise ROS as they evolved to work at an intermedi-
ate redox state [142, 143]. Thus having a good mito-
chondrial reserve might suggest that this nadir can be
maintained when the system is put under stress.
An essential component of mitochondrial control is
uncoupling. This is a process whereby the proton
gradient in the mitochondrion is uncoupled from ATP
production, and it initially seemed to be a key process to
reduce ROS production, as well as generating heat. It
was therefore thought to act as a very good safety valve
for mitochondria and play a fundamental role in survival
and prevention of oxidative damage. In fact, 20% or
more of the energy captured by electron transport is dis-
sipated. However, uncoupling can also be associated
with an increase in ROS, hence, it is a key component of
redox signalling – and has led to updated versions of the
“uncoupling to survive” hypothesis. It may therefore play
a key role in mitohormesis, resulting not just in cell au-
tonomous adaptations, but also systemic adaptation
from signals, for instance, sent out from stressed skeletal
muscle via mitokines. Uncoupling also controls calcium
signalling. It now seems that mild uncoupling can, in-
deed, lead to increased longevity [144]. It is thus perhaps
relevant that a mitochondrial uncoupling protein, UCP2,
can negatively control the inflammasome [145], and in
general, seems to suppress immune activity [146].
Uncoupling thus plays an important role in mitochon-
drial efficiency, which can either be defined as the re-
spiratory control ratio (RCR - ratio of mitochondrial
respiration supporting ATP synthesis to that required to
offset the proton leak) or the ATP/oxygen ratio (the
amount of ATP generated per unit of oxygen consumed)
– this can lead to some confusion, as it can lead to op-
posite conclusions about efficiency. However, whichever
metric is used, it does describe the capacity to convert
resources into ATP, and in effect, the coupling efficiency
[147]. In fact a study has shown that skeletal muscle
mitochondria in obese, sedentary and insulin resistance
women somewhat paradoxically show reduced mito-
chondrial coupling, but a higher production of mito-
chondrial hydrogen peroxide. In effect, despite a degree
of uncoupling, their mitochondria were showing signs of
oxidative stress; this might have been due to nutrient
overload. However, an exercise training programme cor-
rected this, and was correlated with an improvement of
mitochondrial function, in particular, an enhanced abil-
ity to undertake beta oxidation of fats and restoration of
metabolic flexibility, the ability to switch between carbo-
hydrate and fat as energy sources, and better insulin sen-
sitivity [148]. The apparent increase in uncoupling could
be part of a homeostatic response to reduce excessive
ROS production, as UCPs can be activated by oxidative
stress [149]. This would further support evidence that
exercise induces an adaptive response that enabled the
mitochondrial system to cope better.
Finally, it is perhaps worth emphasising the link
between mitochondrial reserve and ability to control oxi-
dative stress. Mitochondria can generate ROS and are
closely linked to Nrf2, which is a master transcription
factor controlling antioxidant responses [150]. This
Nunn et al. Immunity & Ageing           (2020) 17:33 Page 8 of 21
suggests that exercise will not only induce greater mito-
chondrial reserve, but greater anti-oxidant capacity –
and perhaps, a greater reserve ability to uncouple to
manage oxidative stress.
Ageing, immune system reserve and immunosenescence
As previously indicated, like the original SARS virus, this
new virus also seems to induce worse outcomes in pa-
tients who are older, have hypertension and cardiovascu-
lar disease, and induces a phenotype characterised by
raised inflammatory and coagulation markers, multi-
organ failure, as well as neurological complications and
myocardial injury [151]. In short, most things we identify
with the ageing process and the metabolic syndrome,
both of which are associated with declining mitochon-
drial function [152, 153]. It thus pertinent that the rate
of ageing can be modified by lifestyle and disease, and
that epigenetics are making it possible to determine,
with some degree of accuracy, the biological age and
compare it with the chronological age through DNA
methylation (DNAmAge), and predict the likelihood of
future mortality [154, 155]. Although mitochondria obvi-
ously play a role in this, and reduced mitochondrial
DNA copy number (mtDNAcn) does appear to be a
proxy for mitochondrial buffering capacity, and is nega-
tively correlated with DNAmAge, the precise relation-
ship with biological age is still unclear. For instance,
evidence does indicate a clear role for mitochondria in
ageing-related disease and mortality, but not necessarily
chronological age [156]. However, data does suggest that
inducing mitochondrial dysfunction alone in T-cells can
induce premature senescence, driving “inflammaging”
and a tendency towards a cytokine storm [37]. One well
known concept in ageing is the idea of declining organ
reserve, which at the molecular level, is related to a loss
of excess metabolic capacity – in particular, bioenerget-
ics and mtDNA, as well excess telomere capacity [157].
In this respect, it could be argued that the immune sys-
tem could be viewed as an organ, and is also subject to
declining reserve.
As the immune system ages there is a subclinical accu-
mulation of pro-inflammatory factors, as well as de-
creased numbers of circulating respiring mitochondria
found in extracellular vesicles (EVs), which are derived
from immune cells [36]. Coupled to this, there is also
evidence that with increasing age the monocyte
inflammasome-mediated inflammatory response is al-
tered. For instance, this response to influenza A is
retained but the anti-viral interferon response declines
[158]. Furthermore, ageing is also associated with a grad-
ual loss of anti-oxidant capability that is associated with
a decrease in the T helper 1 (Th1) anti-viral response,
which might underlie some of the anti-viral activity of
glutathione and other anti-oxidants [159, 160]. This is
certainly commensurate with reduced immune system
reserve.
However, there is still a lot that is not understood
about ageing, which is why it has led some authors to
categorise it using several separate hallmarks, with mito-
chondrial function only being one of several integrated
systems as the precise cause is still not fully understood
[161]. However, many authors continue to focus on the
mitochondrion – mainly because it represents an ancient
nexus that arose from the endosymbiotic event between
a prokaryote and Archaean that gave rise to eukaryotes,
and understanding this does provide insight into the im-
mune system and inflammation, and the ageing process
[152, 162]. Some have suggested that ageing is actually
related to the loss of mitochondrial respiratory reserve
capacity [109]. This, we suggest, does have a great deal
of merit, and in relation to resistance to viruses, could
be viewed from a reduction in bioenergetic/redox
capacity of the immune system as people age. Tellingly,
reduced skeletal muscle mtDNAcn is associated with
symptoms of the metabolic syndrome, whereas exercise
increases mtDNAcn and is negatively associated with
markers of the metabolic syndrome and enhanced
aerobic capacity [163]. Thus although certainly not the
entire story, ageing is associated with declining mito-
chondrial function, which is likely to be related to re-
duced immune “reserve” and flexibility. Hence, as a
proxy for potential severity when infected, mitochondrial
function does have its place in the ageing process.
The lessons for humans are thus fairly clear: exercise
is part of our evolutionary heritage, and plays key role in
maintaining optimal mitochondrial health and immune
balance (Fig. 2).
Mitochondrial function and therapeutic strategy
As is becoming clear, maintaining good health, in par-
ticular, optimal levels of aerobic fitness and muscle/fat
balance is a good preventative strategy, in effect, the re-
sults of living a healthy lifestyle. A retrospective study
following the Hong Kong influenza outbreak in 2008
found that physical activity was protective and displayed
a “U” shaped dose-response curve [165]. High aerobic
fitness is associated with reduced morbidity and mortal-
ity [166, 167] and physical activity, if not overdone, is
generally anti-inflammatory in the longer term [15, 168]
and results in an enhanced anti-oxidant status [169].
Equally, calorie restriction, which is associated with im-
proved lifespan, is also anti-inflammatory [170, 171], as
is a diet high in polyphenols and probiotics [172].
However, there are still many people, who, for various
reasons are not living a particularly healthy lifestyle –
the effects of which become worse with age. This there-
fore raises the question, would enhancing/supporting
mitochondrial health help in this population if they
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become infected and would understanding the role of
mitochondria help in deciding treatment regimens?
There are a number of possibilities, ranging from
suppressing the auto-inflammatory loop (e.g., direct
targeting of inflammatory pathways, with, say antibodies,
or kinase inhibitors), to mitochondrial protection, en-
hancing mitochondrial turnover and renewal and pre-
conditioning, to direct management of redox. In fact, it
seems that many established drugs probably already do
modulate mitochondrial function, which may provide us
with further insight.
The other main strategy and one perhaps with the
greatest potential preventative benefit in the long run, is
vaccination. The implications of mitochondrial health
here could be extremely important in whether or not a
vaccine is successful in particular populations, for in-
stance the elderly and those with co-morbidities.
Repurposing drugs
Many of the compounds now being studied may influ-
ence mitochondrial function. For instance research on
immunomodulation during influenza infections has
Fig. 2 Resistance to SARS-CoV-2: mitochondrial and redox reserve, hormesis and the metabolic/inflammatory see-saw.
Data strongly support that people who are aerobically fit, and follow a healthy lifestyle, tend to have a greater metabolic and anti-oxidant reserve
related to training-induced mitochondrial adaptation; this is associated with less disease and a longer “healthspan”. The underlying principle that
leads to this is described by hormesis and is the product of humans having evolved, along with most other animals, in an environment where
this adaptation was constantly induced due to the need to move, and food was less available. As a phenotype, they tend to have greater muscle
to fat ratio, and exhibit few, if any symptoms of the metabolic syndrome, such as increased liver fat and visceral adipose tissue (VAT) volume, insu-
lin resistance, or markers of chronic inflammation. In this context, data suggest that muscle, as an organ, tends to be anti-inflammatory when
used regularly, whereas adipose, in particular, in VAT is inflammatory if it becomes overloaded. As the virus seems to induce oxidative stress [164]
and aerobic glycolysis to enhance its own replication, it could be argued that in a person with poor mitochondrial and anti-oxidant reserve, infec-
tion will tend to tip towards chronic inflammation and incomplete resolution. In this scenario, it is important to suppress either inflammation it-
self, or provide extra anti-oxidant power to damp down the potential for a feed-forward inflammatory spiral
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looked at corticosteroids, peroxisomal proliferating ac-
tivated receptors (PPAR) agonists, cyclooxygenase
(COX) inhibitors, adenosine monophosphate kinase
(AMPK) activators, direct antioxidants, and natural
products [173]. All of these can modulate mitochon-
drial function [174–178]. Non-steroidal anti-
inflammatory drugs (NSAIDs) in general, to varying de-
grees, affect mitochondrial function [179]. Critically,
network-based drug repurposing has recently identified
several candidates, such as irbesartan, paroxetine, siroli-
mus, melatonin and quinacrine, amongst others [180].
It has been suggested that angiotensin receptor
blockers (ARBs) are mitochondrially protective [181],
while anti-depressants, such as paroxetine, can inhibit
mitochondrial function [182]. Sirolimus, or rapamycin,
is actually one of the best studied calorie restriction mi-
metics as it modulates mammalian target of rapamycin
(mTOR); it is anti-inflammatory and modulates mito-
chondrial function, and could play a key role in mito-
hormesis [183]. It can, in fact, increase mitochondrial
respiration and reduce production of hydrogen perox-
ide [184]. Critically, data does suggest that this new
virus can indeed inhibit autophagy and the mTOR
pathway [121]. This might suggest that it can enhance
ATP production while reducing ROS, which would ob-
viously benefit it (by at least, initially, suppressing im-
mune activation). Overall, it could be argued that
compounds that do inhibit mitochondrial function
might have a number of effects, such as inducing mito-
hormesis, so activating mitochondrial turnover and re-
newal, but they could also disable mitochondrial
support for viral replication, and perhaps, enhance
apoptosis. However, this has to be balanced with the
possibility that they could cause too much damage, and
potentially, worsen the situation.
One group of drugs that has been investigated as a
possible treatment for SARs-CoV-2 are the antimalarial
aminoquinolones, which have been investigated for
decades as immunomodulators and anti-virals. Their
basic mode of action involves proton capture and de-
acidification of the lysosomal/endosomal compartment,
which interferes with viral replication, autophagy and in-
flammatory pathways, but they also affect the plasma
membrane, MAP kinases, calcium signalling, as well as
DNA [185]. They can also modulate mitochondrial func-
tion [186–188] and have been shown to have anti-
oxidant activity [189]. Paradoxically, they can also induce
oxidative stress, which has raised concerns about their
use in COVID-19 treatment due to the hypoxia associ-
ated with the acute respiratory distress syndrome
(ARDS); one suggested mechanism is increased ROS
generated by mitochondria – as well as possible direct
effects on mitochondria [190]. A meta-analysis has
shown that hydroxychloroquine used in treatment of
COVID-19 resulted in a 2.5 times greater mortality
compared to control groups, whereas its use was associ-
ated with a 1.2 times improvement in patients with mild
to moderate symptoms compared to a control group
[191]. A pharmacovigilance study also found that the
use of hydrochloroquine/chloroquine for treatment of
COVID19 was associated with higher rates of cardiovas-
cular side effects [192]. Interestingly, in another study,
although hydroxychloroquine and chloroquine were not
associated with any significant effect on mortality,
hydroxychloroquine, but not chloroquine, was associated
with a significant reduction in transfer to the intensive
care unit of patients admitted to hospital [193]. Critic-
ally, a recent review of the literature show these mole-
cules to have biphasic/hormetic effects in multiple
models, for instance, they can both stimulate or inhibit
cancer cell and virus growth depending on dose [194].
This not only highlights the role of dose, but also, poten-
tially, the induction of oxidative stress and the patient’s
underlying health, and whether or not these compounds
enhance risk or benefit.
Another very old anti-inflammatory drug, colchicine,
is also being investigated for efficacy in COVID-19 pa-
tients, as it seems to inhibit the NLRP3 inflammasome,
perhaps by suppressing the transport of mitochondria
[195]. Interestingly, SARs-CoV-2 does seem to modulate
many proteins related to the cytoskeleton, and can in-
duce filopodial protusions [94]. Colchicine is often used
to study autophagy, as it depolarises microtubules, so
inhibiting the process. It has now been shown that it can
result in impairments in skeletal mitochondrial function,
increasing ROS, and in older animals, this can result in
insulin resistance [196]. This all suggests that many of
these drugs, especially those that might affect mitochon-
drial function, either directly, or indirectly, and could
have an age-dependent effect - especially those that
might affect autophagy.
An important class of drugs are the MAPK inhibitors,
many of which have been developed as anti-cancer
agents. As indicated previously, MAPKs can modulate
mitochondrial function. They have been proposed as po-
tential treatments as the virus seems to upregulate p38
activity and inhibit counter-regulatory pathways. Al-
though this may well help in viral replication, it can also
result in excessive inflammation in some patients [197,
198]. Interestingly, vemurafenib, a MAPK inhibitor, has
been shown to inhibit dynamin-related protein 1 (DRP1)
phosphorylation, reversing excessive mitochondrial fis-
sion in melanoma cells and resulting in hyper-fusion
and enhancing oxidative phosphorylation and reversal of
aerobic glycolysis [199]. This again highlights the paral-
lels between cancer and viral infection in the sense that
both induce extensive metabolic reprogramming and
manipulation of the cell cycle, often towards aerobic
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glycolysis with modulation of mitochondrial function, as
well as attenuating/modifying immune responses.
Data also suggest that cyclophilin inhibitors, such as
cyclosporine A, which apart from being immune-
suppressants, could also inhibit the replication of related
corona viruses. Data has already shown that some trans-
plant patients receiving immunosuppressants seemed to
have some protection against the virus, although these
were observational studies and other factors, such as
good hygiene, could be important. But in vitro data does
hint at efficacy, especially on other corona viruses, such
as Middle East respiratory syndrome coronavirus
(MERS), as does evidence around the importance of the
cyclophilins in aiding viral replication. The mode of ac-
tion is thought to involve inhibition of the calcineurin
and suppression of the nuclear factor of activated T cells
(NFAT) (reviewed in [200]). In mice infected with
MERS-CoV, it seems that cyclosporine induces a robust
interferon gamma response, which is associated with in-
hibition of viral replication and release [201]. MAVs are
a key component of resistance to viruses, and can acti-
vate both interferon and NF-kB pathways, putting
mitochondria centre stage in viral defence [202]; data in-
dicate that immunophilins are regulators of MAVs [203,
204]. Given the importance of cyclophilin D, a well-
known target of cyclosporine that modulates mitochon-
drial permeability transition [205], it would be interest-
ing to speculate that apart from the well described
immunophilin targets of compounds like tacrolimus and
cyclosporine, a role for modulation of mitochondria
could not be ruled out. In this light, the effectiveness of
the pan-cyclophilin inhibitor, Alisporivir, which does not
have immunosuppressive effects, is potentially interest-
ing as it has high potency against SARS-CoV-2. It has
been suggested that its ability to inhibit cyclophilin D,
and thus control mitochondrial permeability, maybe of
importance in preventing lung damage [206].
Finally, some very promising preliminary data from
the RECOVERY trial suggests that low dose dexametha-
sone could help prevent death of up to 30% of ventilated
patients [207]. On the 18th September 2020, the
European Medicines agency endorsed the use of
dexamethasone in COVID-19 patients on oxygen or
mechanical ventilation (EMA/483739/2020). The most
well-known effect of glucocorticoids is to suppress in-
flammation, largely through the glucorticoid receptor
(GR), but with chronic use they do have side effects, as
they are catabolic [208]. The key point here is that glu-
cocorticoids are generally induced by stress, and in the
short term, are highly protective. It is thus relevant that
GRs also transfer to the mitochondrion and control
mitochondrial gene transcription, and have biphasic ac-
tions [209]. It is thus relevant that dexamethasone has
been shown to both induce mitochondrial uncoupling
and increase oxidative phosphorylation [210], but also
cause mitochondrial dysfunction [211]. This is hardly
surprising as mitochondria are central to both steroid
biosynthesis and action, and thus, stress management
[174]. Although it might be surmised that the predomin-
ant effect in the RECOVERY trial is through direct sup-
pression of inflammatory pathways, it is not impossible
that effects on mitochondria could not be ruled out.
Anti-oxidants and natural products
A further approach that has been suggested is suppres-
sion of oxidative stress by using compounds that are
anti-oxidants. Direct anti-oxidants, for example N-acetyl
cysteine, which, although it has shown some efficacy, has
met with limited success due to dose issues [212]. How-
ever vitamin C, which is now known to concentrate in
mitochondria and act as a ROS scavenger [213], could
be useful. A retrospective analysis of data has suggested
that vitamin C can both reduce the time in the intensive
care unit and the time on ventilators, particularly for
very ill patients [214, 215]. It is now being suggested that
it is used in combination with quercetin, which also
seems to have efficacy in viral infections [216]: quercetin
is a natural product that has anti-oxidant properties and
concentrates in mitochondria and can induce mitochon-
drial biogenesis [217, 218].
Another important principle is that many plant com-
pounds seem to have anti-viral properties, as well as
anti-cancer properties, and modulate calcium signalling
and mitochondrial function – with common targets,
such as VDAC. Plants suffer both from viral infection
and cancer, so it could be that there is some cross over
in function from plants to animals [219]. As viruses
seem to hijack their host’s cellular machinery, including
mitochondrial function, then partially inhibiting mito-
chondrial function could be an evolved strategy to defeat
the virus, especially if it induces apoptosis and/or
upregulates mitophagy and mitochondrial renewal and
anti-oxidant systems. A good example of this is perhaps
salicylic acid, which is a major plant defence signalling
compound [220] and modulates mitochondrial function,
both inhibiting the electron transport chain and acting
as an uncoupling agent [221, 222], as well as regulating
VDAC expression [223]. Some plant viruses produce
proteins that can inhibit the oxidative burst and
salicyclic-acid dependent autophagy [224]. There is thus,
potentially, useful insight provided by the observation
that some medicines that are derived from plant (or
other organism) defence compounds, also appear to have
some benefit in human viral infections. Indeed, Gurbel
and colleagues have suggested that aspirin could be used
against SARS-CoV-2, for instance, by reducing its activa-
tion of NF-κB [225].
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There is also interest in the potential for compounds
such as cannabidiol (CBD) in helping COVID-19 pa-
tients, as the cannabinoids do seem to have some anti-
viral activity, and are anti-oxidant and anti-inflammatory
[226]. CBD, amongst its many identified targets [227],
does seem to directly modulate mitochondrial function,
for instance, it has been shown to bind to VDAC1 and
inhibit the electron transport chain [228, 229]. There is
also evidence that it can inhibit inflammasome activation
[230].
One key mechanism is that many plant compounds
activate Nrf2 and are thus hormetic [231]. Furthermore,
as many manufactured drugs were developed from de-
fence compounds found in plants and other organisms,
this principle could be extended to include them. An-
other example of this could be the statins, which also in-
hibit mitochondrial function [232–234], and one study
has indeed shown they can reduce mortality of COVID-
19 patients [235].
Another ubiquitous antioxidant molecule, melatonin,
which also protects mitochondria [236], is also being in-
vestigated as an adjuvant to protect against a cytokine
storm in SARs-CoV-2 infection [237]. Interestingly, it
has been shown to reverse the Warburg effect in
immune cells, potentially having an anti-inflammatory
effect, and providing a justification for its use in
COVID-19 patients [92]. Likewise, glutathione is also
showing promise, in particular, as it seems to help re-
dress the age related Th1/Th2 imbalance [160]. Of
potential relevance is the observation that a modified
vitamin E derivative that concentrates in mitochondria
has shown benefits in a model of cardiac inflammation
induced by sepsis. It seems to do this by suppressing
mitochondrial DNA damage and its subsequent release
[238]; mtDNA is a potent activator of the inflammatory
system [239].
Also of interest here is Vitamin D, which has been
suggested as a potential adjuvant treatment for patients
with the virus, as it may restore immune function. In
particular, it may enhance anti-inflammatory cytokine
production and so limit the possibility of a cytokine
storm. Analyses do seem to show that it can have some
benefit in people who have low levels of this vitamin
[240]. Critically, it modulates mitochondrial function,
having diverse affects depending on the tissue; it can
stimulate muscle mitochondrial function [241], but may
also enhance lipid storage and adipogenesis [242]. Inter-
estingly, it has been suggested that COVID-19 morbidity
increases with northerly latitude, suggesting a link with
ultraviolet light and vitamin D [243]. Vitamin B3 has
also been shown to have some protective effects in mito-
chondrial myopathy models [244], and has been sug-
gested that it could help prevent lung injury in COVID-
19 patients [245].
Finally, artificial mitochondrial anti-oxidant molecules,
such as MitoQ and SKQ1 could also provide benefit
[246]. There are also compounds like Luminol deriva-
tives, which only become ROS scavengers in areas of
high oxidative stress and are showing some promise in
modulating redox-driven inflammation [247–249]. How-
ever, unlike MitoQ and SKQ1, it is likely that Luminol-
like compounds act outside the mitochondrion [250].
Vaccination
The age related decline in immune function is well de-
scribed, although not well understood, and affects virtu-
ally all components and has a big impact on the success
of vaccination – which has led to a constant drive to im-
prove vaccines for the older generation, in particular
against influenza [251]. It is, however, recognised to be
modifiable by many factors, ranging from exercise, to
stress, and chronic infections [252]. Critical in these re-
sponses is metabolic flexibility, for instance, the ability to
switch between oxidative phosphorylation and glycolysis,
and how this effects different sub-populations of cells
and the pro-inflammatory/anti-inflammatory balance.
For instance, aged B-cells lose oxidative phosphorylation
capacity, and rely more on glycolysis and generate more
ROS. They also infiltrate adipose tissue, heightening in-
flammation in a process involving the NLRP3 inflamma-
some. In relation to the B-cell response, which is key
purpose of vaccination, it seems that obesity, and the
metabolic syndrome, accelerates immunosenescence and
reduces the ability to produce antibodies [253].
A primary research area is on the development of vac-
cines for the elderly against influenza; on average, over
the age of 65 years, the efficacy drops off rapidly. To
study this, immunosenescence related markers in the
blood have been correlated with outcome. Interestingly,
T-cell responses have been found to be a stronger corre-
lates of protection than antibodies. Although the biology
is immensely complex, and may require a system level
“vaccinomics” approach, dysregulated metabolism is
clearly part of the problem – and it has been suggested
that treatments to correct dysregulated metabolic or
other physiological processes may be required before ad-
ministration of vaccines [254].
It would therefore seem that in order to improve the
efficacy of vaccines, it is either necessary to tailor the
vaccine to the particular immunosenescence profile a
patient shows, or, perhaps to reduce their epigenetic age
by ensuring they live a healthy lifestyle and so enhance
their immune system.
Implications of SARs-CoV-2 modulation of
mitochondrial function
There are a number of factors to consider from this. If,
as seems to be the case, this virus is modulating
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mitochondrial function, and thus, mitochondrial health
is important, there are a number of intriguing
possibilities.
Does mitochondrial function explain why morbidity may
be greater among men than women?
There are obviously confounding behavioural factors,
but statistically, men seem to have higher rates of mor-
tality than women when infected with the coronavirus
[255, 256]. Mitochondria in females may be more robust,
which could explain why females tend to live longer than
males [257].
Pollution, mitochondria and severity
Would pollution lower resistance to the virus? Nitrogen
dioxide is oxidative and can induce pulmonary inflam-
mation and reduce function [258], oxidise mitochondrial
cytochrome C [259], while acute inhalation can cause
mitochondrial dysfunction in the brain [260]. Data from
the United Kingdom is now suggesting that high levels
of pollution are linked to increased COVID-19 lethality
[261]. Linked to this is the very disturbing evidence that
iron-rich nanoparticles, largely derived from motor vehi-
cles, are now being found in cardiac mitochondria in the
very young, and are causing oxidative stress [262].
The renin-angiotensin-aldosterone system (RAAS) and
mitochondrial function
The coronavirus binds to ACE2 [263, 264] and mito-
chondria have their own angiotensin system [85].
ACE2 cleaves angiotensin II to produce anti-
inflammatory molecules and protects mitochondria
[84, 86]. This suggests ACE1/2 polymorphisms will be
a factor in reaction to the virus [265]. ARBs, ACEi
and statins may enhance ACE2 activity. Their role in
treatment is thus debated [266, 267].
Hypoxic-ischaemic reperfusion injury and oxygen
During hypoxia, mitochondrial function is inhibited, but
then becomes a source of ROS during reperfusion.
Could damaged mitochondria in the lung and/or heart
lead to an exacerbation of symptoms if too much oxygen
is given to a patient? This is clearly a difficult clinical
conundrum, but does suggest that supplementary oxy-
gen should only be used where absolutely necessary.
Compounds such as melatonin, CBD and curcumin have
shown some protective effects ischaemic-reperfusion
models [268–270] – curcumin is an uncoupling agent
[271]. CBD modulates mitochondria [228]. Key in this is
emerging data that hypoxic preconditioning requires a
drop in the mitochondrial proton motive force [272].
Management of ETC uncoupling is thus vital for life to
control oxidative stress [273]. PPARs may play a key role
in controlling uncoupling [274]. Furthermore there is
much evidence that anaesthetics can modulate mito-
chondrial function and could play a role in both pre-
and post-ischaemia protection, and some can act as un-
coupling agents [275–277].
Phytochemical viral protease inhibitors and mitochondria
Two recent structure-docking studies have indicated
that several phytochemicals could inhibit the SARs-
CoV-2 protease [278, 279]. As many phytochemicals can
also modulate mitochondrial function [280], and primar-
ily evolved to protect the plant, it could be surmised that
they are multi-functional and modulate multiple path-
ways to achieve this.
Long term effects – “long covid”
It is becoming clear that following recovery from the pri-
mary infection with SARS-CoV-2, many people are suf-
fering from long term effects, such as fatigue and mental
health problems, as well as more obvious lung problems.
This has resulted in the formation of a national UK con-
sortium and the launch of the PHOSP-COVID study to
investigate the long terms effects on health of this virus
(see https://www.phosp.org/) [281]. One possible conse-
quence of viral infection could be longer term mitochon-
drial dysfunction, which could lead to a variety of
symptoms. Mitochondrial function, and their relation-
ship to immunity, is again becoming a focus for research
in the chronic fatigue syndrome, which is still not com-
pletely understood [282]. This has been further sup-
ported by evidence of mitochondrial dysfunction in
PBMCs of people with chronic fatigue syndrome [283].
Can we test the hypothesis that mitochondrial
health = immune health and enhanced resistance
to the virus?
In terms of testing and/or looking for evidence that
mitochondria could help explain some of the patho-
physiology of this virus, there are several potential ways
to look for this relationship, ranging from laboratory
based to population studies.
Direct evidence that SARs-CoV-2 modulates mitochondrial
function
This work could be carried out in vitro with cultured
cells and/or isolated mitochondria prepared from con-
trol and infected individuals. In particular, using imaging
to look for co-localisation in “virus factories”.
Lifestyle and mitochondrial function
It could be predicted that those populations exhibiting
the lowest levels of optimal health and the highest levels
of the metabolic syndrome and “diabesity”, will show the
highest susceptibility. For example, it might be revealing
to map the case fatality rate to the latest trends in
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obesity/ diabetes after the necessary confounders are
taken into account [284]. In support of this, the emer-
ging data from New York in relation to SARS-CoV-2 in-
fection is that obesity is strongly correlated with critical
illness [9]. In contrast, would those populations showing
the highest fitness levels and functioning be more resist-
ant? For instance, would measured VO2 max show an
inverse relationship with morbidity?
Inherited mitochondrial dysfunction
Individuals with known mitochondrial dysfunction are
well known to show abnormal susceptibility to infections
[25]. Is there a link between mitochondrial haplotype
and resistance? There is certainly evidence for different
mtDNA haplotypes amongst different populations [285].
Although there is an emerging disparity in morbidity be-
tween Black people and other minorities in the USA, it
is thought it may be more to do with socio-economic
imbalances and higher rates of lifestyle induced co-
morbidities [286].
Markers of mitochondrial health in the blood
Blood-derived mitochondrial markers of reduced func-
tion may correlate with disease severity before, during
and after infection.
Epigenetic age and mitochondrial function
Data now show it is possible to determine someone’s
epigenetic age and compare it with their chronological
age. There is a close correlation with this ratio and co-
existing morbidity [287]. Thus, would blood-derived epi-
genetic markers of metabolic age correlate with disease
severity before, during and after infection?
Conclusion
The main conclusion from this review is that as immune
function is dependent on mitochondrial function, and al-
though this does decline with age, the rate it does so can
be modified by lifestyle. This is perhaps best highlighted
by the link between ageing, mitochondrial function and
the metabolic syndrome. This implies that both resist-
ance to the virus, and the effectiveness of a vaccine, will
be linked to the mitochondrial health of the individual.
Furthermore, as evidence indicates that many viruses,
which most likely include SARs-CoV-2, modulate bio-
energetics and redox in both the immune system and
other cells they infect to enhance their own replication,
they could potentially induce excessive stress in these
systems if their mitochondria are already sub-optimally
functional. This would suggest that in patients experien-
cing severer symptoms, mitochondrial support could be
a strategy, which could take many forms, both direct
(e.g., mitochondrial anti-oxidants), or indirect (anti-in-
flammatories, inhibitors of viral replication etc.). This
viewpoint becomes apparent when one considers that
mitochondria are a central nexus and have many func-
tions, ranging from supplying energy, anabolites for new
growth, controlling intracellular redox, calcium signal-
ling, detection of viruses and activation of anti-viral
mechanisms, as well as ultimately controlling the life
and death of the cell.
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